XOMA News and Press, XOMA Corporation From 12/02/19

EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights...

Xoma (NASDAQ: XOMA ) initiates a subscription rights  offering to holders of its common stock, Series X and Series Y preferred stock. Investors will be entitled to purchase common shares at $22.00, 15% below today's close of $26.03. More news on: XOMA Corporation, Healthcare stocks n...

EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by XOMA Corporation (Nasdaq: XOMA) please note that in the fifth paragraph of the Financial Results section of the release, the net loss of $4.6 million is for the third quarter o...

EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today reported its third quarter 2019 financial results.  “XOMA’s portfolio of future potential royalty- and milestone-generating assets grew by 25% in the third quarter with the addi...

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.  One of the assets, NIR178, is being develope...

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cantor Fitzgerald Global Healthcare Conference, taking place October 2-4, 2019, in New York, New York. &#...

EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the H.C. Wainwright 21 st Annual Global Investment Conference, in New York, New York. ...

EMERYVILLE, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), today announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech, Inc. drug candidates for which XOMA could receive future ...

Novartis’s iscalimab highlighted at key scientific conferences First patient dosed with gevokizumab in collaborator clinical study Sesen Bio announced intention to initiate Vicinium® BLA filing process in 2019 Royalty and milestone interest acquired in five anti-th...

EMERYVILLE, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 Wedbush PacGrow Healthcare Conference in New York, New York.  The presenta...